Finance

Beta
Lists
CRNX:NASDAQ
Crinetics Pharmaceuticals Inc
$36.70
+4.89%
(+1.71) 1D
$36.96
+0.71% (+0.26)
After hours
Closed: Jun 26, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRNX...
Open
$35.52
High
$36.91
Low
$35.11
Mkt. cap
3.87B
Avg. vol.
1.05M
Volume
5.05M
52-wk high
$57.99
52-wk low
$25.83
EPS
-$5.13
Beta
0.24
Shares outstanding
105.44M
No. of employees
594
Open
$35.52
High
$36.91
Low
$35.11
Mkt. cap
3.87B
Avg. vol.
1.05M
Volume
5.05M
52-wk high
$57.99
52-wk low
$25.83
EPS
-$5.13
Beta
0.24
Shares outstanding
105.44M
No. of employees
594
News stories
From sources across the web
Profile
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018. Wikipedia
About Crinetics Pharmaceuticals Inc
CEO-
Employees594
FoundedNov 18, 2008
Headquarters-
SectorPharmaceutical industry
Websitecrinetics.com
Analyst ratings
Based on 11 analysts giving stock ratings to CRNX in the past 3 months
Strong buy
Buy
11
Hold
0
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for CRNX in the last 3 months.
Highest
Current $36.70
$97.00 (+164.31%)
Average
$88.90 (+142.23%)
Lowest
$80.00 (+117.98%)
Analyst
Recommendation
Action
Price target
Projected
Date
Maxwell Skor
Morgan Stanley
Buy
Maintained
$80.00
+118%
06/15/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$81.00
+120.7%
06/15/2026
Joseph Schwartz
Leerink Partners
Buy
Maintained
$95.00
+158.9%
06/11/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Reiterated
$88.00
+139.8%
05/15/2026
Leland Gershell
Oppenheimer
Buy
Maintained
$84.00
+128.9%
05/11/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$97.00
+164.3%
05/08/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$83.00
+126.2%
05/08/2026
Kate Dellorusso
LifeSci Capital
Buy
Reiterated
$89.00
+142.5%
05/09/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$95.00
+158.9%
05/08/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/08/2026
Catherine Novack
JonesTrading
Buy
Reiterated
$97.00
+164.3%
05/08/2026
Richard Law CFA
Goldman Sachs
Buy
Maintained
$67.00
+82.6%
03/01/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Maintained
$90.00
+145.2%
02/26/2026
Last report
May 7, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$1.23 / -$1.23
-0.07%miss
Revenue / Est. (USD)
10.73M / 8.52M
+26.03%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.03M
143.00K
6.16M
10.73M
Cost of goods sold
80.30M
90.46M
86.13M
100.28M
Cost of revenue
80.30M
90.46M
86.13M
100.28M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
49.84M
52.26M
53.70M
50.83M
Operating expense
49.84M
52.26M
53.70M
50.83M
Total operating expenses
130.14M
142.73M
139.83M
151.11M
Operating income
-129.11M
-142.59M
-133.67M
-140.38M
Other non operating income
20.00K
-49.00K
-125.00K
-131.00K
EBT including unusual items
-115.64M
-130.09M
-122.64M
-127.84M
EBT excluding unusual items
-115.64M
-130.09M
-122.64M
-127.84M
Income tax expense
-
-
180.00K
-
Effective tax rate
-
-
-0.15%
-
Other operating expenses
-
-
-
-
Net income
-115.64M
-130.09M
-122.82M
-127.84M
Net profit margin
-11,216.00%
-90,972.73%
-1,993.43%
-1,191.03%
Earnings per share
-1.23
-1.38
-1.29
-1.23
Interest and investment income
13.46M
12.54M
11.16M
12.66M
Interest expense
-
-
-
-
Net interest expenses
13.46M
12.54M
11.16M
12.66M
Depreciation and amortization charges
-
-
-
-
EBITDA
-128.15M
-141.57M
-132.67M
-139.22M
Gain or loss from assets sale
23.00K
-
8.00K
20.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of CRNX
Explore what’s possible
Create portfolio
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer